Evidence map›Paper›PMID 36508462›Full record

ArticlePloS one2022

Algorithmic identification of atypical diabetes in electronic health record (EHR) systems.

Sara J Cromer, Victoria Chen, Christopher Han, William Marshall, Shekina Emongo, Evelyn Greaux, Tim Majarian, Jose C Florez, Josep Mercader, Miriam S Udler

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Validation of an Algorithm to Identify End-Stage Kidney Disease in Electronic Health Records Data.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Sara J CromerDiabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Victoria ChenDiabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Christopher HanDiabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, Massachusetts, United States of America.ORCID 0000-0002-1585-4370
William MarshallDiabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Shekina EmongoDiabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Evelyn GreauxDiabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Tim MajarianPrograms in Metabolism and Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America.
Jose C FlorezDiabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Josep MercaderDiabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Miriam S UdlerDiabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, Massachusetts, United States of America.ORCID 0000-0003-3824-9162
Broad Institute · USMassachusetts General Hospital · USHarvard University · US

Funding

Research Training & Career Development ProgramU54CA118638 · NCI · MOREHOUSE SCHOOL OF MEDICINE · PI Desiree Avia Rivers · 2005 to 2026
$22.7M
RARE and Atypical Diabetes Network(RADIANT)U54DK118638 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI ASHOK BALASUBRAMANYAM, JEFFREY P KRISCHER · 2018 to 2026
$22.7M
TRAINING PROGRAM IN ENDOCRINOLOGY AND DIABETEST32DK007028 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Karen K Miller · 1986 to 2026
$18.5M
Development of Polygenic Risk Scores for Diabetes and Complications across the Life-Span in Populations of Multiple AncestriesU01HG011723 · NHGRI · BROAD INSTITUTE, INC. · PI Alisa Knodle Manning, Josep Maria Mercader · 2021 to 2026
$5.7M
Clinical Implications of Genetically Defined Diabetes Subtypes and Application to Electronic Health Medical Record SystemsK23DK114551 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI UDLER, MIRIAM SARGON · 2017 to 2021
$1000k
The Effect of Socioeconomic Status on Outcomes in Type 2 Diabetes Clinical TrialsF32DK127545 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CROMER, SARA JANE · 2020 to 2020
$76k
NCI NIH HHS U54 CA118638NHGRI NIH HHS U01 HG011723NIDDK NIH HHS F32 DK127545NIDDK NIH HHS K23 DK114551NIDDK NIH HHS T32 DK007028NIDDK NIH HHS U54 DK118638
6 · The paper itself

Abstract

aimsUnderstanding atypical forms of diabetes (AD) may advance precision medicine, but methods to identify such patients are needed. We propose an electronic health record (EHR)-based algorithmic approach to identify patients who may have AD, specifically those with insulin-sufficient, non-metabolic diabetes, in order to improve feasibility of identifying these patients through detailed chart review.

methodsPatients with likely T2D were selected using a validated machine-learning (ML) algorithm applied to EHR data. "Typical" T2D cases were removed by excluding individuals with obesity, evidence of dyslipidemia, antibody-positive diabetes, or cystic fibrosis. To filter out likely type 1 diabetes (T1D) cases, we applied six additional "branch algorithms," relying on various clinical characteristics, which resulted in six overlapping cohorts. Diabetes type was classified by manual chart review as atypical, not atypical, or indeterminate due to missing information.

resultsOf 114,975 biobank participants, the algorithms collectively identified 119 (0.1%) potential AD cases, of which 16 (0.014%) were confirmed after expert review. The branch algorithm that excluded T1D based on outpatient insulin use had the highest percentage yield of AD (13 of 27; 48.2% yield). Together, the 16 AD cases had significantly lower BMI and higher HDL than either unselected T1D or T2D cases identified by ML algorithms (P<0.05). Compared to the ML T1D group, the AD group had a significantly higher T2D polygenic score (P<0.01) and lower hemoglobin A1c (P<0.01).

conclusionOur EHR-based algorithms followed by manual chart review identified collectively 16 individuals with AD, representing 0.22% of biobank enrollees with T2D. With a maximum yield of 48% cases after manual chart review, our algorithms have the potential to drastically improve efficiency of AD identification. Recognizing patients with AD may inform on the heterogeneity of T2D and facilitate enrollment in studies like the Rare and Atypical Diabetes Network (RADIANT).

Indexed as

Diabetes Mellitus, Type 1Electronic Health RecordsAlgorithmsHumansInsulinMachine LearningInsulin

Identifiers

PMID36508462
PMCPMC9744270
OpenAlexW4311180314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.